Phio Pharmaceuticals (FRA:44R3) Institutional Ownership : 0.76% (As of Jun. 04, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Phio Pharmaceuticals's institutional ownership is 0.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Phio Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Phio Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.83%.

Phio Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Phio Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Institutional Ownership Chart

Phio Pharmaceuticals Historical Data

The historical data trend for Phio Pharmaceuticals can be seen below:

	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-12-31	2024-01-31
Institutional Ownership	1.79	1.37	2.30	2.93	2.93	1.52	1.74	1.50	0.76	0.76

Phio Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Phio Pharmaceuticals (FRA:44R3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

PHIO:USA

Address

257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines